Introduction
Hepatocellular carcinoma, the third most frequent cause of cancer-related death worldwide, is an increasing medical and economic problem. For patients who have underlying liver disease and hepatocellular carcinoma, liver transplant usually is the best treatment option. Most centers use the Milan criteria, equivalent to the T2 criteria of the American Study of Liver Diseases staging system, as the criteria for listing for transplant because patients who meet the Milan criteria have a lower risk of tumor recurrence than patients who are outside the Milan criteria. 1 However, some studies suggest that these criteria may be too restrictive. 2, 3 In patients who have hepatocellular carcinoma and are outside the Milan criteria, we determine tumor grade from a biopsy and use this grade as part of the algorithm to determine candidacy for liver transplant. 4 Various locoregional therapies for hepatocellular carcinoma are used before transplant to prevent tumor progression before transplant and decrease the risk of recurrence after transplant. Locoregional therapies used at our institution include transarterial catheter radiofrequency ablation and chemoembolization. Locoregional therapies may decrease the stage of tumors and make transplant feasible in some patients.
The purpose of the present study was to assess the relation between locoregional therapy and recurrence of hepatocellular carcinoma after transplant.
Materials and Methods
We retrospectively reviewed 50 patients who had end-stage liver disease from hepatocellular carcinoma and cirrhosis and who were evaluated and treated with liver transplant at Başkent University from January 2000 to May 2013. The diagnosis of hepatocellular carcinoma was made with contrast-enhanced magnetic resonance imaging (MRI) before liver transplant and was confirmed by histologic evaluation of the excised liver. The study was approved by the Ethical Review Committee of the institute. All protocols conformed with the ethical guidelines of the 1975 Helsinki Declaration.
Patients were placed on the transplant waiting list on the basis of preoperative imaging characteristics. Patients who were diagnosed with hepatocellular carcinoma and who had liver transplant were evaluated retrospectively for recurrence of hepatocellular carcinoma. Patients were divided into 2 groups: patients who had or did not have locoregional therapy before transplant. Patients also were divided into 2 groups based on whether they met or were outside the Milan criteria.
All liver transplant candidates who had the diagnosis of hepatocellular carcinoma were discussed at the multidisciplinary tumor conference that included transplant surgeons, gastroenterologists, radiologists, and oncologists. Radiofrequency ablation was performed for smaller lesions (diameter < 3 cm) in favorable anatomic locations and not near major vascular structures, the biliary system, or adjacent structures such as the stomach or diaphragm. Transarterial catheter chemoembolization was performed for lesions not amenable to radiofrequency ablation and multifocal hepatocellular carcinoma in patients who had preserved liver function. The response to locoregional therapy was assessed by contrast enhanced MRI or computed tomography scan every 3 months until the patients had liver transplant.
Median follow-up after transplant was 120 months. After initial discharge, the patients were evaluated in the transplant clinic by the transplant surgeons twice weekly during the first 2 months and weekly during the third month after transplant. After the patients were discharged from the transplant clinic, they were followed with laboratory studies every 2 to 4 weeks by their physician and seen in the transplant clinic as needed. Patients were seen by the transplant surgeons at 6 months and evaluated with liver biopsy, laboratory studies including alphafetoprotein level, and imaging (computed tomography or MRI scan) to evaluate for recurrence of hepatocellular carcinoma.
Statistical analyses
Groups were compared with the chi-square test. Statistical significance was defined by P ≤ .05.
Results
Most patients who had liver transplant met the Milan criteria ( Table 1) . The most common primary liver disease was hepatitis B virus infection (Table 1) . There were no differences between the groups in primary diagnosis, Child-Turcotte-Pugh score, Model for End-Stage Liver Disease score, donor age, median time on the waiting list, and median waiting time with priority points ( Table 1 ). The alphafetoprotein level was significantly greater in patients who were outside the Milan criteria (Table 1) .
Most patients had locoregional therapy before transplant (Table 2) . Some patients did not receive locoregional therapy because they had a short waiting time before transplant, they were poor candidates for locoregional therapy because of technical or functional reasons, or the diagnosis of hepatocellular carcinoma was not made until after transplant, based on histopathologic evaluation of the excised liver specimen. Locoregional therapy was received more frequently in patients who were outside the Milan criteria than patients who met the Milan criteria (Table 2) .
Follow-up at median 90 months after transplant showed that 9 patients (18%) had recurrence at median 45 (range, 120 ± 12 mo) months (recurrence: locoregional therapy, 5 of 31 patients [16%]; no locoregional therapy, 4 of 19 patients [21%]; not significant). The 5-year frequency of recurrence was Table 2) . Patients who were outside the Milan criteria had lower 5-year survival than patients who met the Milan criteria. Locoregional therapy before transplant did not have an effect on survival after transplant in patients who met Milan criteria, but locoregional therapy was associated with improved survival in patients who were outside the Milan criteria (Table 2) .
Discussion
The present study showed that tumor behavior was less favorable and outcomes were worse in patients who had hepatocellular carcinoma outside the Milan criteria than patients who met the Milan criteria.
Patients outside the Milan criteria had higher recurrence and lower survival than patients who met the Milan criteria. However, locoregional therapy before transplant improved outcomes in patients outside the Milan criteria but did not change the outcomes in patients who met the Milan criteria. In considering the expansion of criteria for transplant for hepatocellular carcinoma, identification of patients who have favorable tumor behavior is important to achieve excellent outcomes. Macroscopic tumor features (size and number of tumors) are associated with outcomes, and macroscopic features typically are used as criteria for liver transplant in patients who have hepatocellular carcinoma. 1 Patients who have larger and more tumors typically have a worse prognosis. There is a correlation between tumor size and number and vascular invasion. Tumor size, tumor number, tumor grade, and alpha-fetoprotein level are independent predictors of vascular invasion. 5 Response to locoregional therapy during treatment to decrease tumor staging in hepatocellular carcinoma may be a marker of tumor behavior and selection for liver transplant. Various protocols may assess hepatocellular carcinoma outside Milan criteria for locoregional therapy before transplant to select patients who may have favorable outcomes after liver transplant. 6, 7 In addition, a sustained response (stability of lesions ≥ 3 mo after treatment to decrease tumor stage) may be another useful parameter to predict favorable tumor behavior. Alpha-fetoprotein level (absolute value and progressive increase while on the waiting list) also may correlate with tumor recurrence and mortality after transplant. 8 In the present study, the benefits of locoregional therapy before transplant were limited to patients who had hepatocellular carcinoma outside the Milan criteria; locoregional therapy in these patients was associated with better recurrencefree survival. 8 Locoregional therapy also may prevent tumor progression and dropout and may be justified in patients who have transplant waiting time > 6 months.
In summary, expansion of transplant criteria in patients who have hepatocellular carcinoma outside the Milan criteria may increase access to transplant for patients who have more advanced hepatocellular carcinoma and may be associated with favorable results. In the present study, patients outside the Milan criteria had features that were consistent with 
